glycine has been researched along with Parkinsonian Disorders in 26 studies
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present study was to determine whether S-4-carboxy-3-hydroxyphenylglycine (S)-4C3HPG, a mixed group I glutamate metabotropic receptor antagonist and a group II agonist, attenuated parkinsonian-like muscle rigidity in rats." | 3.71 | (S)-4C3HPG, a mixed group I mGlu receptor antagonist and a group II agonist, administered intrastriatally, counteracts parkinsonian-like muscle rigidity in rats. ( Lorenc-Koci, E; Pilc, A; Wardas, J; Wolfarth, S, 2001) |
| "To study parkinsonism, dementia, dystonia, and amyotrophy as subphenotypes of SCA2, and to explore the effect of CAG repeats at different loci and of mitochondrial polymorphism A10398G as modifiers of phenotype." | 1.46 | Neurological phenotypes in spinocerebellar ataxia type 2: Role of mitochondrial polymorphism A10398G and other risk factors. ( Augustin, MC; Barsottini, O; Jardim, LB; Locks-Coelho, LD; Monte, TL; Pedroso, JL; Pereira, FS; Reckziegel, EDR; Santos, ASP; Saraiva-Pereira, ML; Vargas, FR, 2017) |
| "Perry syndrome is a rare form of autosomal dominant Parkinsonism with respiratory failure recently defined as being due to mutations in the DCTN1 gene." | 1.36 | Perry syndrome due to the DCTN1 G71R mutation: a distinctive levodopa responsive disorder with behavioral syndrome, vertical gaze palsy, and respiratory failure. ( Fish, M; Hack, M; Majounie, E; Morris, HR; Newsway, V; Rohrer, JD; Warren, JD; Williams, N, 2010) |
| "The mean age at onset for parkinsonism was 60 years, range 30-79 years; fewer than 20% of the patients had symptoms before the age 50 years, while by 75 years >90% of them had developed symptoms." | 1.35 | Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. ( Benecke, R; Berg, D; Bonifati, V; Brown, L; Cras, P; De Deyn, PP; Engelborghs, S; Farrer, MJ; Foroud, T; Gaig, C; Gasser, T; Gibson, JM; Goldwurm, S; Guidi, M; Hagenah, J; Haugarvoll, K; Kachergus, JM; Klein, C; Nichols, WC; Nuytemans, K; Pals, P; Pickut, B; Rademakers, R; Riboldazzi, G; Ross, OA; Samii, A; Tan, EK; Theuns, J; Tolosa, E; Uitti, RJ; Van Broeckhoven, C; Walter, U; Wszolek, ZK; Zabetian, CP, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (50.00) | 29.6817 |
| 2010's | 12 (46.15) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Bourque, M | 3 |
| Grégoire, L | 3 |
| Patel, W | 3 |
| Dickens, D | 3 |
| Snodgrass, R | 3 |
| Di Paolo, T | 4 |
| Coon, EA | 1 |
| Rocca, W | 1 |
| Melson, CS | 1 |
| Ahlskog, JE | 1 |
| Matsumoto, JY | 1 |
| Low, PA | 1 |
| Singer, W | 1 |
| Monte, TL | 1 |
| Pereira, FS | 1 |
| Reckziegel, EDR | 1 |
| Augustin, MC | 1 |
| Locks-Coelho, LD | 1 |
| Santos, ASP | 1 |
| Pedroso, JL | 1 |
| Barsottini, O | 1 |
| Vargas, FR | 1 |
| Saraiva-Pereira, ML | 1 |
| Jardim, LB | 1 |
| Zheng, Q | 1 |
| Yin, J | 1 |
| Zhu, L | 1 |
| Jiao, L | 1 |
| Xu, Z | 1 |
| Goldstein, DA | 1 |
| Dunn, SE | 1 |
| Karberg, K | 1 |
| Sun, XR | 1 |
| Chen, L | 1 |
| Chen, WF | 1 |
| Xue, Y | 1 |
| Yung, WH | 1 |
| Munhoz, RP | 1 |
| Teive, HA | 1 |
| Francisco, AN | 1 |
| Raskin, S | 1 |
| Rogaeva, E | 1 |
| Wider, C | 1 |
| Dachsel, JC | 2 |
| Farrer, MJ | 4 |
| Dickson, DW | 2 |
| Tsuboi, Y | 1 |
| Wszolek, ZK | 2 |
| Newsway, V | 1 |
| Fish, M | 1 |
| Rohrer, JD | 1 |
| Majounie, E | 1 |
| Williams, N | 1 |
| Hack, M | 1 |
| Warren, JD | 1 |
| Morris, HR | 1 |
| Venero, JL | 1 |
| Mauriño, R | 1 |
| Machado, A | 1 |
| Santiago, M | 1 |
| Valldeoriola, F | 2 |
| Gaig, C | 3 |
| Muxí, A | 1 |
| Navales, I | 1 |
| Paredes, P | 1 |
| Lomeña, F | 1 |
| De la Cerda, A | 1 |
| Buongiorno, M | 1 |
| Ezquerra, M | 2 |
| Santacruz, P | 1 |
| Martí, MJ | 2 |
| Tolosa, E | 3 |
| Wang, G | 1 |
| Fan, XN | 1 |
| Tan, YY | 1 |
| Cheng, Q | 1 |
| Chen, SD | 1 |
| Johnson, KA | 1 |
| Jones, CK | 1 |
| Tantawy, MN | 1 |
| Bubser, M | 1 |
| Marvanova, M | 1 |
| Ansari, MS | 1 |
| Baldwin, RM | 1 |
| Conn, PJ | 1 |
| Niswender, CM | 1 |
| van Nuenen, BF | 1 |
| Helmich, RC | 1 |
| Ferraye, M | 1 |
| Thaler, A | 1 |
| Hendler, T | 1 |
| Orr-Urtreger, A | 1 |
| Mirelman, A | 1 |
| Bressman, S | 1 |
| Marder, KS | 1 |
| Giladi, N | 1 |
| van de Warrenburg, BP | 1 |
| Bloem, BR | 1 |
| Toni, I | 1 |
| Wu, RM | 1 |
| Bounds, R | 1 |
| Lincoln, S | 1 |
| Hulihan, M | 1 |
| Lin, CH | 1 |
| Hwu, WL | 1 |
| Chen, J | 1 |
| Gwinn-Hardy, K | 1 |
| Farrer, M | 1 |
| Kaneda, K | 1 |
| Tachibana, Y | 1 |
| Imanishi, M | 1 |
| Kita, H | 1 |
| Shigemoto, R | 1 |
| Nambu, A | 1 |
| Takada, M | 1 |
| Rajput, A | 1 |
| Robinson, CA | 1 |
| Ross, OA | 3 |
| Lincoln, SJ | 1 |
| Cobb, SA | 1 |
| Rajput, ML | 1 |
| Schüpbach, M | 1 |
| Lohmann, E | 1 |
| Anheim, M | 1 |
| Lesage, S | 1 |
| Czernecki, V | 1 |
| Yaici, S | 1 |
| Worbe, Y | 1 |
| Charles, P | 1 |
| Welter, ML | 1 |
| Pollak, P | 1 |
| Dürr, A | 1 |
| Agid, Y | 1 |
| Brice, A | 1 |
| Karunakaran, S | 1 |
| Diwakar, L | 1 |
| Saeed, U | 1 |
| Agarwal, V | 1 |
| Ramakrishnan, S | 1 |
| Iyengar, S | 1 |
| Ravindranath, V | 1 |
| González-Fernández, MC | 1 |
| Lezcano, E | 1 |
| Gómez-Esteban, JC | 1 |
| Gómez-Busto, F | 1 |
| Velasco, F | 1 |
| Alvarez-Alvarez, M | 1 |
| Rodríguez-Martínez, MB | 1 |
| Ciordia, R | 1 |
| Zarranz, JJ | 1 |
| Mata, IF | 1 |
| de Pancorbo, MM | 1 |
| Vernon, AC | 1 |
| Zbarsky, V | 1 |
| Datla, KP | 1 |
| Croucher, MJ | 1 |
| Dexter, DT | 1 |
| Haugarvoll, K | 1 |
| Rademakers, R | 1 |
| Kachergus, JM | 1 |
| Nuytemans, K | 1 |
| Gibson, JM | 1 |
| Tan, EK | 1 |
| Goldwurm, S | 1 |
| Guidi, M | 1 |
| Riboldazzi, G | 1 |
| Brown, L | 1 |
| Walter, U | 1 |
| Benecke, R | 1 |
| Berg, D | 1 |
| Gasser, T | 1 |
| Theuns, J | 1 |
| Pals, P | 1 |
| Cras, P | 1 |
| De Deyn, PP | 1 |
| Engelborghs, S | 1 |
| Pickut, B | 1 |
| Uitti, RJ | 1 |
| Foroud, T | 1 |
| Nichols, WC | 1 |
| Hagenah, J | 1 |
| Klein, C | 1 |
| Samii, A | 1 |
| Zabetian, CP | 1 |
| Bonifati, V | 1 |
| Van Broeckhoven, C | 1 |
| Muñoz, E | 1 |
| Lladó, A | 1 |
| Rey, MJ | 1 |
| Cardozo, A | 1 |
| Molinuevo, JL | 1 |
| Lorenc-Koci, E | 1 |
| Wardas, J | 1 |
| Wolfarth, S | 1 |
| Pilc, A | 1 |
| Calon, F | 1 |
| Morissette, M | 1 |
| Ghribi, O | 1 |
| Goulet, M | 1 |
| Grondin, R | 1 |
| Blanchet, PJ | 1 |
| Bédard, PJ | 1 |
| Lavedan, C | 1 |
| Buchholtz, S | 1 |
| Nussbaum, RL | 1 |
| Albin, RL | 1 |
| Polymeropoulos, MH | 1 |
1 trial available for glycine and Parkinsonian Disorders
| Article | Year |
|---|---|
Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations.
Topics: Adult; Aged; Deep Brain Stimulation; Female; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine P | 2007 |
25 other studies available for glycine and Parkinsonian Disorders
| Article | Year |
|---|---|
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
Conjugal multiple system atrophy: Chance, shared risk factors, or evidence of transmissibility?
Topics: Autonomic Nervous System Diseases; Female; Glycine; Glyphosate; Herbicides; Humans; Male; Middle Age | 2019 |
Neurological phenotypes in spinocerebellar ataxia type 2: Role of mitochondrial polymorphism A10398G and other risk factors.
Topics: Adult; Aged; Alanine; Ataxin-2; Dementia; Dystonia; Female; Genetic Predisposition to Disease; Glyci | 2017 |
Reply for the comment on "Reversible Parkinsonism induced by acute exposure glyphosate".
Topics: Glycine; Glyphosate; Humans; Parkinsonian Disorders | 2018 |
"Reversible Parkinsonism" following glyphosate exposure.
Topics: Glycine; Glyphosate; Humans; Parkinsonian Disorders | 2018 |
Electrophysiological and behavioral effects of group III metabotropic glutamate receptors on pallidal neurons in normal and parkinsonian rats.
Topics: Action Potentials; Aminobutyrates; Animals; Globus Pallidus; Glycine; Male; Neurons; Oxidopamine; Pa | 2013 |
Unilateral pallidotomy in a patient with parkinsonism and G2019S LRRK2 mutation.
Topics: Female; Functional Laterality; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase- | 2009 |
Elucidating the genetics and pathology of Perry syndrome.
Topics: Adult; Age of Onset; Aged; Animals; Brain; Chlorocebus aethiops; COS Cells; Depression; DNA-Binding | 2010 |
Perry syndrome due to the DCTN1 G71R mutation: a distinctive levodopa responsive disorder with behavioral syndrome, vertical gaze palsy, and respiratory failure.
Topics: Arginine; Behavioral Symptoms; DNA Mutational Analysis; Dopamine Agents; Dynactin Complex; Glycine; | 2010 |
Striatal ablation of GABAergic neurons prevents the in vivo neuroprotective effect of DCG-IV against the MPP+-induced neurotoxicity on dopaminergic nerve terminals.
Topics: Animals; Corpus Striatum; Cyclopropanes; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; | 2010 |
123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Female; Glycine; Heart; Humans; Leucine-Rich | 2011 |
Parkinsonism after chronic occupational exposure to glyphosate.
Topics: Adult; Chemical Industry; Female; Glycine; Glyphosate; Herbicides; Humans; Occupational Exposure; Pa | 2011 |
The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
Topics: Aminobutyrates; Animals; Benzoates; Catalepsy; Disease Models, Animal; Dopamine; Dopamine D2 Recepto | 2013 |
Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism.
Topics: Adult; Analysis of Variance; Biomechanical Phenomena; Brain; Cerebral Cortex; DNA Mutational Analysi | 2012 |
Parkin mutations and early-onset parkinsonism in a Taiwanese cohort.
Topics: Adult; Arginine; Cohort Studies; DNA Mutational Analysis; Exons; Family Health; Female; Glycine; Hum | 2005 |
Down-regulation of metabotropic glutamate receptor 1alpha in globus pallidus and substantia nigra of parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Behavior, Animal; Benzoate | 2005 |
Parkinsonism, Lrrk2 G2019S, and tau neuropathology.
Topics: Aged; alpha-Synuclein; Brain; Cell Line; Disability Evaluation; Disease Progression; Female; Glycine | 2006 |
Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcysteine; Alkynes; Animals; Antioxidants; Antipa | 2007 |
Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain.
Topics: Adult; Aged; Arginine; DNA Mutational Analysis; Family Health; Female; Genetic Predisposition to Dis | 2007 |
Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Topics: Animals; Benzoates; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Excitatory Amino Ac | 2007 |
Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Arginine; Cysteine; DNA Mutational Analysis | 2008 |
Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
Topics: Dementia; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; Genetic Testing; Glyci | 2008 |
(S)-4C3HPG, a mixed group I mGlu receptor antagonist and a group II agonist, administered intrastriatally, counteracts parkinsonian-like muscle rigidity in rats.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Disease Models, Animal; Electromyography; Glycine; | 2001 |
Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Corpus Striatum; Dopamine Agoni | 2002 |
A mutation in the human neurofilament M gene in Parkinson's disease that suggests a role for the cytoskeleton in neuronal degeneration.
Topics: Adult; Age of Onset; Brain; Cytoskeleton; DNA Mutational Analysis; Female; Genetic Testing; Glycine; | 2002 |